Academic literature on the topic 'Terbinafin'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Terbinafin.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Terbinafin"
Mayser, P. "Terbinafin." Der Hautarzt 67, no. 9 (July 25, 2016): 724–31. http://dx.doi.org/10.1007/s00105-016-3844-9.
Full textDürrbeck, A., and P. Nenoff. "Terbinafin." Der Hautarzt 67, no. 9 (July 29, 2016): 718–23. http://dx.doi.org/10.1007/s00105-016-3853-8.
Full textSchmid-Wendtner, M. H., and H. Korting. "Terbinafin-Topika." Der Hautarzt 59, no. 12 (November 7, 2008): 986–91. http://dx.doi.org/10.1007/s00105-008-1552-9.
Full textLukács, Péter, Zsuzsánna Károlyi, Tibor Barna, and István Mórocz. "Terbinafine induced SCLE apropos of two cases." Bőrgyógyászati és Venerológiai Szemle 91, no. 5 (November 20, 2015): 174–77. http://dx.doi.org/10.7188/bvsz.2015.91.5.2.
Full textKorting, H. C. "Synergistische Effekte der Antimykotika Terbinafin und Itraconazol." Der Hautarzt 50, no. 1 (January 22, 1999): 56–57. http://dx.doi.org/10.1007/s001050050866.
Full textWilmer, A., and U. Wollina. "Systemische Terbinafin-Therapie von Dermatophytosen im Kindesalter." Mycoses 41 (October 1998): 54–57. http://dx.doi.org/10.1111/j.1439-0507.1998.tb00603.x.
Full textBreuer, K., B. Völker, R. Gutzmer, A. Kapp, and T. Werfel. "Pigmentierung des Gesichtes unter Therapie mit Terbinafin." Der Hautarzt 56, no. 11 (November 2005): 1056–59. http://dx.doi.org/10.1007/s00105-004-0888-z.
Full textSultana, Razia, and Md Wahiduzzaman. "Emerging threat in antifungal resistance on superficial dermatophyte infection." Bangladesh Medical Journal Khulna 51, no. 1-2 (March 4, 2019): 21–24. http://dx.doi.org/10.3329/bmjk.v51i1-2.40469.
Full textBorelli, Siegfried, and Stephan Lautenschlager. "Dermatophyten-Infektion der Haut und der Nägel." Therapeutische Umschau 73, no. 8 (October 2016): 457–61. http://dx.doi.org/10.1024/0040-5930/a000818.
Full textMashkilleyson, A. L., and M. A. Gomberg. "The effect of terbinafin in some extensive dermatomycoses." Journal of Dermatological Science 6, no. 1 (August 1993): 116. http://dx.doi.org/10.1016/0923-1811(93)91394-a.
Full textDissertations / Theses on the topic "Terbinafin"
Balda, Ana Claudia. "Avaliação das concentrações de terbinafina no pelame de gatos da raça Persa com dermatofitose e daqueles portadores de Microsporum canis tratados em esquema de pulsoterapia ou terapia contínua." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/10/10136/tde-21072011-132952/.
Full textDermatophytosis is a superficial mycosis caused mainly by Microsporum canis and is very common in Persian cats. The goals of this study were: to evaluate the clinical and mycological cure in the animais treated with terbinafine in pulse therapy compared with continuous therapy; the accumulation of terbinafine in cats hair and the time that it is maintained in therapeutical concentrations after its suspension; correlates the clinical cure with the quantity of the drug in the hair and compare the side effects in pulse therapy in relation to continuous therapy. In this study were included 27 Persian cats, 17 healthy carriers of M. canis and 10 cats with dermatophytosis. The group I was composed of 13 females treated with pulse therapy, during the first seven days in the dosis of 20 mg/kg, daily, followed by a period of suspension of the medication for 21 days, subsequently, it was realized a new cycle of therapy, more seven days of terbinafine in the dosis of 40 mg/kg daily, repeating a period of suspension for another 21 days . The group 11 was composed of 14 males, that received continuous therapy, during 56 days, in the first 28 days they received the oral dosis of 20 mg/kg daily and 40 mg/kg daily for the next 28 days. The animais were submitted to two mycological cultures collected by the carpet square method with 15 days of interval, before and after the therapy. It was realized also manual avulsion of the cats hair for the quantification of terbinafine by high performance liquid chromatography (HPLC) in the days zero, seven, 28, 35 and 56. Every 15 days, blood samples were taken for hepatic function evaluation. There were clinical and mycological cure in 100% of treated animais; the concentrations of terbinafine in cats hair were maintained above therapeutical concentrations in pulse therapy in the dosis of 20, and also in 40 daily oral administration, but there was a higher accumulation of the drug when it was used in the higher dosis in continuous therapy. Although were seen emesis in the first week of therapy, and also higher serical activities of hepatic enzymes. There were no alterations in the values of AL T and FA in the pulse therapy group. Terbinafine had good efficacy and was secure for the treatment of healthy carriers of M. canis and also in animais with dermatophytosis.
Breia, Maria Inês Mendonça dos Santos. "Utilização de um composto à base de florfenicol, betametasona e terbinafina no tratamento de otite externa diagnosticada por citologia." Master's thesis, Universidade de Lisboa, Faculdade de Medicina Veterinária, 2017. http://hdl.handle.net/10400.5/14346.
Full textA otite externa é uma das doenças mais frequentes nos cães, afetando 10 a 20% dos animais. Os microrganismos mais frequentemente isolados são Malassezia pachydermatis e Staphylococcus pseudintermedius, agentes comensais que em presença de condições propícias podem iniciar sobrecrescimento. A deteção de Malassezia spp. e de Staphylococcus spp. por citologia é prática comum na clínica para diagnóstico e avaliação de resposta ao tratamento de otites externas. Este estudo teve como objetivo determinar a eficácia de um composto à base de florfenicol, betametasona e terbinafina no tratamento de otite externa diagnosticada por citologia em 48 aplicações em cães do Hospital Veterinário Sul do Tejo. A natureza da infeção correspondia a 71% infeções por Malassezia spp., 19% infeções mistas e 10% infeções bacterianas. Este composto medicamentoso revelou ser eficaz em 81% das aplicações, sendo que as restantes ocorreram em animais com dermatite atópica e cujo episódio de otite era recorrente. Tanto a dermatite atópica como o facto de ser recorrente demonstraram ter uma relação significativa com o insucesso terapêutico (p < 0,001 e p = 0,043, respetivamente). Esta combinação farmacológica demonstrou potencial interesse, uma vez que se revelou eficaz na maioria dos casos e, aliado à grande vantagem da sua posologia, deverá ser considerada na escolha terapêutica da otite externa. Palavras-
ABSTRACT - Otitis externa is one of the most common diseases in dogs, affecting 10 to 20% of animals. The most commonly isolated microorganisms are Malassezia pachydermatis and Staphylococcus pseudintermedius, which are commensal, although the presence of certain conditions can lead to their overgrowth and pathogenic change. Cytological identification of Malassezia spp. and Staphylococcus spp. is a common clinical approach for the diagnosis and assessment in the treatment of external otitis. The present study aims to determine the efficacy of a medicine containing florfenicol, betamethasone and terbinafine in the treatment of external otitis diagnosed by cytology in 48 applications in dogs examined in Hospital Veterinário Sul do Tejo. The nature of the infections was 71% Malassezia spp., 19% mixed infection and 10% bacterial infection. This topical treatment was effective in 81% of all applications. Failure occurred in dogs with atopy and recurrent otitis. Both atopy and recurrence were demonstrated to have a significant relation with lack of success (p < 0,001 e p = 0,43, respectively). This pharmacological combination has demonstrated potential interest for its efficiency in most cases allied to the great advantage of dosage. Therefore, it should be considered for treatment of otitis externa.
N/A
Balda, Ana Claudia. "Estudo retrospectivo de casuística, comparativo de metodologia diagnóstica e de avaliação de eficácia da griseofulvina e da terbinafina na terapia das dermatofitoses em cães e gatos." Universidade de São Paulo, 2001. http://www.teses.usp.br/teses/disponiveis/10/10136/tde-29072009-090127/.
Full textDermatophytosis in domestic carnivorous are superficial infections caused mainly by two genus of fungus: Microsporum sp and Trichophyton sp. This disease is an anthropozoonosis important for public health. The goals of this study were: characterize the population of cats and dogs with dermatophytosis treated in the Dermatology Service of HOVET FMVZ/USP in a period of 27 months; evaluate the validity of the histopathological exam as a methodology of diagnosis; and compare the efficacy of griseofulvin and terbinafine in the therapy of the dermatophytosis. Seventy six animals (47,3% were felines and 52,7% were canines) were evaluated in this study. The more frequent isolated etiological agent in canines and felines was Microsporum canis. Seasonality was not observed. The dogs with a defined breed were more predisposed (75,0%) and the Yorkshire Terrier dogs had a higher proportion of positive cultures (23,3%). The felines with or without breed definition got the same frequency, however, the Persians (93,7%) were more predisposed among those of pure breed. It was noticed that the majority of infected animals were under one year of age (65,8%). The most observed lesions were: alopecia, crusts, erythema and scales. The majority of the lesions had a circular form and were found in the cephalic, trunk and limb regions. There was no pruritus in 50,0% of the canines and 88,8% of the felines. The lesions were more inflammatory in dogs. The histopathological exam had a low sensitivity (28,6%) and a high number of false negatives (71,4%).Griseofulvin (50 mg/kg/day) was effective in 100,0% of the cases, with no side effects, the average time for cure was 41 days. The terbinafine used at the dosage of 5 mg/kg/day showed an efficacy of 81,3%, no side effects were observed as well and average time for cure was 21 days. The same efficacy using the dosage of 20 mg/kg/day of terbinafine was observed, although side effects were observed in 16,6% of the animals treated with an average time for cure of 33 days. The present study demonstrated that terbinafine is a good therapeutical alternative, although griseofulvin is still the first choice drug for the treatment of dermatophytosis in dogs and cats.
Marchini, Julio Flávio Meirelles. "Isolamento e caracterização de gene que confere resistência à terbinafina em leishmania major." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/17/17136/tde-03082008-173958/.
Full textGene amplification can be recognized as a protein regulation mechanism in Leishmania. Exposure to non-lethal concentrations of different drugs in isolated manner, such as, methotrexate, primaquine, chloroquine and antimony drives the amplification of specific regions. Examples for amplified regions are contained in chromosomes six and 23. The strains become resistant to these drugs and eventu-ally to other drugs as well. Terbinafine is a synthetic substance used as an antifungal agent. Its mechanism of action is by squalene epoxidase inhibition, blocking ergosterol synthesis, a cell membrane component in Leishmania. Parasite exposure to terbinafine elicits H region amplification. H region fragmentation allowed resistance delimitation to 2.8kb, T1 fragment. By insertional mutagenesis terbinafine resistance gene was defined and termed HTBF. HTBF coded protein has a hydrophilic N-terminal and a hydrophobic C-terminal containing four alpha-helixes, putatively, an integral membrane protein. It possesses homology to Saccharomyces cerevisiae Yip protein, which takes part in the vesicular transport from the endoplasmic reticulum to Golgi apparatus. HTBF gene was detected in sensitive L. major strains and other Leishmania species and its transcript was detected in both resistant and sensitive L. major strains. We raised the hypothesis of a multiple drug resistance locus, since amplified regions induced by one drug could elicit resistance to a second drug. Co-transfection of MRPA to the HTBF transfectant led to a five-fold decrease to antimonial resistance level. Even though these resistance genes amplify together in the H region, they have antagonizing mechanisms of action. Since terbinafine action disrupts membrane integrity, we raised a hypothesis in which resistance involves enhancement of membrane repair machinery. Loss of phenotype caused by the lack of calcium suggests the inactivation of this machinery is a predicted phenomenon, corroborating the hypothesis.
Cavalheiro, Ayrton Sydnei. "ATIVIDADE IN VITRO DA TERBINAFINA E ASSOCIAÇÕES SOBRE PYTHIUM INSIDIOSUM." Universidade Federal de Santa Maria, 2009. http://repositorio.ufsm.br/handle/1/8939.
Full textPythiosis is a granulomatous disease of human and animals that occurs primarily in tropical and subtropical areas of the world. It is caused by an aquatic, fungus-like organism called Pythium insidiosum. The treatment for pythiosis is uncertain, with an unfavorable prognosis for human and animals. Therefore, new possibilities for treatments must be examined. We have evaluated the in vitro activities of terbinafine (0.25 to 32 mg/L) alone and in combination with caspofungin (0.5 to 128 mg/L), miconazole (0.25 to 32 mg/L), fluconazole(0.125 to 64 mg/L), ketoconazole (0.125 to 64 mg/L), amphotericin B (0.25 to 16 mg/L), fluvastatin (0.125 to 64 mg/L), rifampicin (0.25 to 64 mg/L), metronidazole (0.25 to 128 mg/L) and ibuprofen (8 to 2,048) against 17 clinical isolates of P. insidiosum. Antifungal activities were assayed by broth microdilution, based on protocol M38-A for filamentous fungi, adapted to P. insidiosum, as well as the checkerboard method. Synergisms were observed in combinations of terbinafine plus caspofungin (41.18%), fluconazole (41.18%), amphotericin B (41.18%), ketoconazole (29.41%) and miconazole (11.76%). The combinations of terbinafine plus rifampicin and terbinafine plus metronidazole were indifferent for 94.12% of strains. Terbinafine plus ibuprofen was indifferent for 82.35% of strains. Antagonisms were observed in combinations of terbinafine with fluvastatin (35.30%) or rifampicin (5.88%). The combinations of terbinafine plus caspofungin, terbinafine plus fluconazole and terbinafine plus amphotericin B may have significant therapeutic potential for treatment of pythiosis.
Pitiose é uma doença granulomatosa de humanos e animais que ocorre principamente em áreas tropicais e subtropicais de todo o mundo. Ela é causada por um microrganismo aquático semelhante aos fungos chamado Pythium insidiosum. O tratamento para pitiose é incerto, com um prognóstico desfavorável tanto para humanos como para os animais. Com isso, novas possibilidades para tratamentos devem ser examinados. Desta forma, avaliou-se a atividade in vitro da terbinafina (0,25 a 32 mg/L) sozinha e em combinação com caspofungina (0,5 a 128 mg/L), miconazol (0,25 a 32 mg/L), fluconazol (0,125 a 64 mg/L), cetoconazol (0,125 a 64 mg/L), anfotericina B (0,25 a 16 mg/L), fluvastatina (0,125 a 64 mg/L), rifampicina (0,25 a 64 mg/L), metronidazol (0,25 a 128 mg/L) e ibuprofeno (8 a 2.048) frente a 17 isolados clínicos de P. insidiosum. As atividades antifúngicas foram avaliadas por microdiluição em caldo, baseado no protocolo M38-A para fungos filamentosos, adaptado para P. insidiosum, e pela técnica de checkerboard. Sinergismos foram observados nas combinações de terbinafina mais caspofungina (41,18%), fluconazol (41,18%), anfotericina B (41,18%), cetoconazol (29,41%) e miconazol (11,76%). As combinações de terbinafina mais rifampicina e terbinafina mais metronidazol foram indiferentes para 94,12% das cepas. Terbinafina mais ibuprofeno foi indiferente para 82,35% dos isolados. Antagonismos foram observados nas combinações de terbinafina mais fluvastatina (35,30%) ou rifampicina (5,88%). As combinações de terbinafina mais caspofungina, terbinafina mais fluconazol e terbinafina mais anfotericina B podem ter significante potencial terapêutico para o tratamento da pitiose.
Dias, Fabrício César. "Caracterização de mecanismos de resistência à terbinafina em diferentes espécies de Leishmania." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/17/17136/tde-06052009-093740/.
Full textGene amplification is a common phenomenon observed in Leishmania cell lines subjected to drug pressure. The H locus of Leishmania (Leishmania) major is normally found amplified in cell lines selected in unrelated drugs, as terbinafine. We selected cell lines of L. (L.) major and Leishmania (Viannia) braziliensis resistant to terbinafine. Short-run Pulsed Field Gel Electrophoresis (PFGE) and Southern blotting analysis showed that this resistance was not generated by H locus amplification. Resistance to squalene epoxidase inhibiter is being generated by other mechanism once others loci can be involved in the terbinafine resistance and through protein partner differential analysis, mutants resistant showed differences in protein expression. The initial target to terbinafine resistance elucidation in the cell lines selected was ergosterol biosynthesis pathway. We choose genes: 3-ketoacyl-CoA thiolase (ERG10), squalene synthase (ERG9 or SQS1), squalene epoxidase (ERG1), oxidosqualene-lanosterol cyclase (ERG7), and lanosterol 14-demethylase (ERG11), of L. major and L. braziliensis, besides YIP1 gene of L. braziliensis. For this, primers were synthesized using the sequences generated by genome project of these species inserted in gene bank. The genes ERG10, SQS1, ERG1, ERG7 and ERG11 of L. major and of L. braziliensis besides YIP1 of L. braziliensis were amplified by PCR and cloned into pGEM-T Easy vector that enabled all genes disruption by insertion of HYG cassette and, with exception of the ERG7 gene of L. braziliensis, genes were subcloned into shuttle-vector pXG1. Restrictions fragments of these genes were used in Northern analysis to verify the transcripts level. We verified through short-run PFGE and Southern analysis that the resistant cell lines do not show amplification of studied loci. The participation of ergosterol biosynthesis pathway genes of L. major and L. braziliensis and YIP1 gene of L. braziliensis in the resistance to terbinafine was verified in functional experiments. With this objective, the genes YIP1, ERG10 and ERG1 of L. braziliensis were transfected into LB2904 cell line of L. braziliensis, and the genes ERG10, SQS1, ERG1, ERG7 and ERG11 and the ERG1 gene disruption by HYG mark of L. major were transfected into LT252 cell line of L. major. Experiments that analyze the susceptibility to amphotericin B associated or not to terbinafine were performed using the wild type cell lines of L. major and L. braziliensis, and with this initials experiments, we selected cell lines of these two species resistant to amphotericin B. In order to analyze the possible regulatory function of the RIME 5/2/6 elements of L. braziliensis, the repeat LbRIME 5/2/6b was amplified by PCR and cloned into pGEM-T Easy vector and with this clone, the element was disrupted with a SAT cassette. The cloning into vector pGEM enabled to analyze the interaction of the nuclear protein with the repeat LbRIME 5/2/6b through gel shift assay.
Agathon, Véronique. "Pharmacocinétique et biotransformations du Lamisil R (terbinafine) et de ses 3 principaux métabolites après administration orale à doses croissantes et répétées chez le sujet sain." Paris 5, 1996. http://www.theses.fr/1996PA05P147.
Full textIbrahim, MohD, Omer sheikh, Pratyksha Sankhyan, Qaryoute Ayah Al, Abdulrahman Ibrahim, Akilesh Mahajan, Nilesh Mahajan, Mohsen Pourmoteza, and Jason Mckinney. "Terbinafine induced fulminant hepatic failure and patient death." Digital Commons @ East Tennessee State University, 2019. https://dc.etsu.edu/asrf/2019/schedule/108.
Full textTaurelle, Valérie. "La terbinafine : pharmacocinétique de la molécule mère et d'un métabolite aprés administration orale unique d'un comprimé à 250 mg, étude de bioéquivalence entre quatre formes galéniques." Paris 5, 1992. http://www.theses.fr/1992PA05P212.
Full textBrasset, Charlotte. "Lamisil R (Terbinafine), linéarité de la pharmacocinétique de la Terbinafine et de ses trois principaux métabolites à dose unique et à l'état d'équilibre chez le volontaire sain." Paris 5, 1996. http://www.theses.fr/1996PA05P146.
Full textBooks on the topic "Terbinafin"
Asia-Pacific Symposium on Lamisil (1993 Vienna, Austria). Terbinafine in the treatment of superficial fungal infections: Proceedings of the Asia-Pacific Symposium on Lamisil : proceedings of a satellite symposium held during the Dermatology 2000 congress in Vienna, May 1993. London: Royal Society of Medicine Services, 1993.
Find full textIverson, Suzanne Leah. In vitro and in vivo investigations into idiosyncratic drug reactions: the role of reactive metabolites produced by the target tissue in terbinafine-induced cholestatic hepatitis and antipsychotic-induced agranulocytosis. 2002, 2002.
Find full textIverson, Suzanne Leah. In vitro and in vivo investigations into idiosyncratic drug reactions: The role of reactive metabolites produced by the target tissue in terbinafine-induced cholestatic hepatitis and antipsychotic-induced agranulocytosis. 2002.
Find full textBook chapters on the topic "Terbinafin"
Jones, Thomas C., and Violette V. Villars. "Terbinafine." In Chemotherapy of Fungal Diseases, 483–503. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-75458-6_23.
Full textCuenca-Estrella, Manuel, and Juan Luis Rodriguez-Tudela. "Terbinafine." In Aspergillosis: From Diagnosis to Prevention, 317–25. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2408-4_19.
Full textPappas, Peter G. "Terbinafine." In Essentials of Clinical Mycology, 113–19. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-6640-7_7.
Full textMonod, Michel, Marc Feuermann, and Tsuyoshi Yamada. "Terbinafine and Itraconazole Resistance in Dermatophytes." In Dermatophytes and Dermatophytoses, 415–29. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-67421-2_20.
Full textde Wolff, F. A. "Hoe vaak moet de leverfunctie worden gecontroleerd bij gebruik van terbinafine?" In Vademecum permanente nascholing huisartsen, 2009–10. Houten: Bohn Stafleu van Loghum, 2006. http://dx.doi.org/10.1007/978-90-313-8808-0_1067.
Full text"Terbinafin." In Checkliste Arzneimittel A–Z, edited by Detlev Schneider and Frank Richling. Stuttgart: Georg Thieme Verlag, 2013. http://dx.doi.org/10.1055/b-0034-82781.
Full text"Terbinafine." In Meyler's Side Effects of Drugs, 745–54. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-444-53717-1.01516-x.
Full textWaugh, Christine D. "Terbinafine." In xPharm: The Comprehensive Pharmacology Reference, 1–4. Elsevier, 2007. http://dx.doi.org/10.1016/b978-008055232-3.62729-1.
Full textBylund, David B. "Terbinafine ☆." In Reference Module in Biomedical Sciences. Elsevier, 2018. http://dx.doi.org/10.1016/b978-0-12-801238-3.97744-4.
Full text"Terbinafine." In Dermatology Therapy, 562. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/3-540-29668-9_2659.
Full textConference papers on the topic "Terbinafin"
Rencber, Seda, and Sakine Tuncay Tanrıverdi. "Terbinafine Hydrochloride Loaded PLGA Nanoparticles for Topical Administration." In The 3rd World Congress on Recent Advances in Nanotechnology. Avestia Publishing, 2018. http://dx.doi.org/10.11159/nddte18.112.
Full textHIPLER, U. CH, CH SCHROETER, B. HIPLER, and U. WOLLINA. "INHIBITORY EFFECT OF TERBINAFINE ON REACTIVE OXYGEN SPECIES (ROS) GENERATION BY CANDIDA ALBICANS." In Proceedings of the 11th International Symposium. WORLD SCIENTIFIC, 2001. http://dx.doi.org/10.1142/9789812811158_0099.
Full textKondoros, Balázs Attila, and Zoltán Aigner. "Physicochemical characterization and dissolution studies of terbinafine hydrochloride–cyclodextrin complexes prepared by solvent-free co-grinding." In II. Symposium of Young Researchers on Pharmaceutical Technology,Biotechnology and Regulatory Science. Szeged: Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Faculty of Pharmacy, 2020. http://dx.doi.org/10.14232/syrptbrs.2020.op23.
Full textChien, Ming-Hsien, Shun Fa Yang, and Wen Sen Lee. "Abstract 3040: Terbinafine inhibits oral squamous cell carcinoma growth through anti-cancer cell proliferation and anti-angiogenesis." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3040.
Full textReports on the topic "Terbinafin"
Terbinafine is probably first choice oral drug for fungal toenail infection. National Institute for Health Research, October 2017. http://dx.doi.org/10.3310/signal-000494.
Full text